Health‐related Quality of Life in Patients with Esophageal Cancer or Precancerous Lesions Assessed by EQ‐5D: A Multicenter Cross‐sectional Study
Youqing Wang,Jufang Shi,Lingbin Du,Huiyao Huang,Le Wang,Juan Zhu,Huizhang Li,Yana Bai,Xianzhen Liao,Ayan Mao,Guoxiang Liu,Jiansong Ren,Xiaojie Sun,Jiyong Gong,Qi Zhou,Ling Mai,Lin Zhu,Xiaojing Xing,Yuqin Liu,Ying Ren,Bingbing Song,Li Lan,Jinyi Zhou,Peian Lou,Xiaohua Sun,Xiao Qi,Shouling Wu,Wenqiang Wei,Kai Zhang,Min Dai,Wanqing Chen,Jie He
DOI: https://doi.org/10.1111/1759-7714.13368
IF: 3.223
2020-01-01
Thoracic Cancer
Abstract:BackgroundWe aimed to obtain a set of health state utility scores of patients with esophageal cancer (EC) and precancerous lesions in China, and to explore the influencing factors of health‐related quality of life (HRQoL).MethodsA hospital‐based multicenter cross‐sectional study was conducted. From 2013 to 2014, patients with EC or precancerous lesions were enrolled. HRQoL was assessed using a European quality of life‐5 dimension (EQ‐5D‐3L) instrument. Multivariable linear regression analysis was performed to explore the influencing factors of the EQ‐5D utility scores.ResultsA total of 2090 EC patients and 156 precancer patients were included in the study. The dimension of pain/discomfort had the highest rate of self‐reported problems, 60.5% in EC and 51.3% in precancer patients. The mean visual analog scale (VAS) score for EC and precancer patients were 68.4 ± 0.7 and 64.5 ± 3.1, respectively. The EQ‐5D utility scores for EC and precancer patients were estimated as 0.748 ± 0.009 and 0.852 ± 0.022, and the scores of EC at stage I, stage II, stage III, and stage IV were 0.693 ± 0.031, 0.747 ± 0.014, 0.762 ± 0.015, and 0.750 ± 0.023, respectively. According to the multivariable analyses, the factors of region, occupation, household income in 2012, health care insurance type, pathological type, type of therapy, and time points of the survey were statistically associated with the EQ‐5D utility scores of EC patients.ConclusionsThere were remarkable decrements of utility scores among esophageal cancer patients, compared with precancer patients. The specific utility scores of EC would support further cost‐utility analysis in populations in China.